FIGURE 1 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Year: 2023
Type: other
Abstract: Dose-escalation schematic for the entire phase I dose-escalation study in patients with advanced solid tumors. Results of cohorts Q2W-LD and Q3W are included in the current report. The results of the main dose-escalation phase are published elsewhere (13). Dose escalation was terminated before reaching the DLs and LD-DLs shown in the shaded boxes. Numbers are the actual number of patients enrolled and treated. C1, cycle 1; DL, dose level; LD-DL, loading dose dose level; MTD, maximum tolerated dose; Q2W, every 2 weeks; Q3W, every 3 weeks.
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4386224927